发明公开
EP2392597A3 Antagonists to IL-17A, IL-17F, and IL-23P19 and methods of use
有权
IL-17A，IL-17F-和IL-23p19的拮抗剂及其使用方法
- 专利标题： Antagonists to IL-17A, IL-17F, and IL-23P19 and methods of use
- 专利标题（中）： IL-17A，IL-17F-和IL-23p19的拮抗剂及其使用方法
-
申请号： EP11168730.7申请日： 2008-04-28
-
公开(公告)号： EP2392597A3公开(公告)日： 2012-03-07
- 发明人: Lewis, Katherine E. , Presnell, Scott R. , Levin, Steven D.
- 申请人： ZymoGenetics, Inc.
- 申请人地址： 1201 Eastlake Avenue East Seattle, Washington 98102 US
- 专利权人： ZymoGenetics, Inc.
- 当前专利权人： ZymoGenetics, Inc.
- 当前专利权人地址： 1201 Eastlake Avenue East Seattle, Washington 98102 US
- 代理机构： Griffin, Philippa Jane
- 优先权： US914681P 20070427; US914663P 20070427; US741189 20070427; US762738 20070613
- 主分类号： C07K16/24
- IPC分类号： C07K16/24 ; A61K39/395 ; C07K16/46 ; A61P37/06
摘要：
There is provided an antagonist of IL-23 and of IL-17A or IL-17F comprising: (i) an antibody or antibody fragment that binds the p19 subunit of IL-23 as shown in SEQ ID NO: 4; and (ii) an antibody or antibody fragment that binds IL-17A as shown in SEQ ID NO: 2 or that binds IL-17F as shown in SEQ ID NO: 6; wherein the antibody or antibody fragment that binds IL-17A or IL-17F comprises a HCDR1 amino acid sequence, a HCDR2 amino acid sequence, and a HCDR3 amino acid sequence of the variable heavy region selected from the group consisting of the variable heavy region of the hybridoma of ATCC Patent Deposit Designation PTA-7988; and wherein the variable light region comprises a LCDR1 amino acid sequence, a LCDR2 amino acid sequence, and a LCDR3 amino acid sequence of the variable light region of the hybridoma of ATCC Patent Deposit Designation PTA-7988.
公开/授权文献
信息查询
